Keep current on the latest news from Allegro Ophthalmics

Sign up today to be notified about the initiation of clinical trials, study results and breaking company news.

Your info will never be shared with a third-party

No Thanks

Clinical Trials

Allegro has a promising new therapy in development – Luminate® – a novel first-in-class integrin inhibitor that simultaneously deactivates multiple pathways leading to DME.

Luminate® is in various stages of clinical development for multiple indications, including diabetic macular edema and age-related macular degeneration.1

  • For doctors interested in participating in Phase 3 DME trials, click here
  • For patients interested in learning about trial sites near you, please come back to visit us in mid-2018

Read more about Luminate® in the news.


Reference: 1. Data on file.